Pharmaceutical

Character Biosciences gains $93m for precision eye disease therapies

Character Biosciences has raised $93m in an oversubscribed Series B funding round to expedite the progression of precision therapies.

Mar 27, 2025 - 06:00
Character Biosciences gains $93m for precision eye disease therapies
Character Biosciences has raised $93m in an oversubscribed Series B funding round to expedite the progression of precision therapies.
Read the original article

Tags:

Previous Article

Cassava ends simufilam Alzheimer’s programme after second Phase III failure

Next Article

MSD makes licence agreement with Hengrui Pharma for Lp(a) inhibitor

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: $100 billion estimate for Ozempic-style weight loss drugs gets wary eye from analysts

STAT+: $100 billion estimate for Ozempic-style weight l...

Dec 5, 2023

Risk adjusted net present value: What is the current va...

Dec 15, 2024

Booster Therapeutics to develop proteasome activator medicines

Booster Therapeutics to develop proteasome activator me...

Oct 12, 2024